17 November 2020
Moderna announced that its mRNA-1273 Covid-19 vaccine candidate met its primary efficacy endpoint according to the first interim data from a Phase III study. The interim data showed that mRNA-1273 had an efficacy rate of 94.5% based on 95 cases of Covid-19. More than 30,000 participants in the US are enrolled in the study, which is being conducted with the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.
Samsung Biologics announced that it has struck a long-term deal with Eli Lilly to produce the antibody-drug neutralising Covid-19. The Korean-based biotech signed a contract manufacturing organisation agreement with the US pharmaceutical company in May to supply the drug for Covid-19.
Bharat Biotech has begun Phase III trials of Covaxin, its Covid-19 vaccine candidate in India. The trial involves 26,000 participants across 22 locations and will be conducted in collaboration with the Indian Council of Medical Research. The trial has been approved by the Drugs Controller General of India and registered with the clinical trials registry of India.
TrippBio is currently developing a US Food and Drug Administration (FDA)-approved drug called TD213 for treating mild and moderate Covid-19 infections. The orally administered drug blocks the replication of the SARS-CoV-2 virus and associated acute inflammatory conditions.
